Healthcare

Dermata Reports Further Findings from Four-Week Tome Skincare Study

Dermata Therapeutics highlighted additional participant assessments and before-and-after photographs from a cosmetic study of its Tome Foundational Treatment.

Published:
Reading Time
3 min

Dermata Therapeutics, Inc. (Nasdaq:DRMA) has reported further findings and participant photographs from a recently completed cosmetic study of Tome Foundational Treatment, its once-weekly skin renewal product. The company said the additional material provides information on changes in skin texture, tone, dark spots, smoothness and overall appearance.

#Four-week study included 31 participants

The open-label study involved 31 participants. Each participant applied Tome Foundational Treatment one time per week for four weeks, with investigator assessments conducted at multiple points during the study.

The evaluation covered fine lines, hyperpigmentation, dark spots, smoothness, firmness, radiance and overall appearance. Participants also completed their own assessments after receiving four treatments.

#Participant-reported findings

After four treatments, 77% of participants said they had noticed improvements in their skin after 4 weeks. Separately, 74% agreed that the treatment felt like a professional skincare treatment, while 74% agreed that applying it was worth the results.

Dermata also reported that 77% of participants noticed less downtime, including redness and peeling, with each weekly treatment.

#Before-and-after photographs

Photographs were taken at the start of the study and after four treatments at the end of the study. Dermata said the images were collected using the Canfield VISIA-CR system to document changes in skin appearance during the four-week treatment period.

The company presented selected participant images to illustrate changes in appearance, while noting that actual results may vary.

#Tolerability and product details

Dermata said the treatment was well tolerated in the study, with no treatment-related adverse events reported.

Tome Foundational Treatment is designed for once-weekly use as an addition to an existing skincare routine. Dermata says the product is intended to renew the appearance of skin and improve its tone and texture over time.

The treatment uses Bioneedle™, which Dermata describes as consisting of 100% freshwater sponge. The company says it wild harvests and minimally processes the material into a fine, purified powder.

#Commercial update

Gerry Proehl, Dermata’s Chairman, President and Chief Executive Officer, said the company believes clinical demonstrations of visible product benefits are important to building consumer confidence, establishing credibility and supporting consumer adoption. He also said Dermata had received over 1,000 orders for Tome Foundational Treatment since launch.

Dermata describes Tome Foundational Treatment as its first commercial product. The company said additional innovations are planned to follow; the timing and success of planned launches and potential market acceptance remain subject to risks and uncertainties identified by Dermata.

#About Dermata Therapeutics

Dermata Therapeutics develops and commercialises direct-to-consumer and professional skincare solutions. The company says it uses experience in clinical dermatology and its Bioneedle technology in developing products for consumer skincare needs. Dermata is headquartered in San Diego, California, and its shares trade on Nasdaq under the symbol DRMA.

#Key Takeaways

  • Dermata reported additional findings from an open-label cosmetic study involving 31 participants.
  • Participants used Tome Foundational Treatment one time per week for four weeks.
  • Reported findings included 77% noticing skin improvements after 4 weeks and 77% noticing less downtime with each weekly treatment.
  • Dermata said no treatment-related adverse events were reported in the study.
  • The company reported over 1,000 orders for Tome Foundational Treatment since launch.

Original source: Read original article

Frequently Asked Questions